Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma

Publisher： Karger

E-ISSN： 1423-0232|89|2|42-46

ISSN： 0030-2414

Source： Oncology, Vol.89, Iss.2, 2015-0, pp. : 42-46

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

All‐oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub‐analysis in Asian patients from the HALLMARK DUAL study

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 36, Iss. 10, 2016-10 ,pp. : 1433-1441

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prevention of hepatitis C‐related HCC

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 30, Iss. 2, 2015-02 ,pp. : 321-328

John Wiley & Sons Inc

Access to resources Recommend Favorite

Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. 4, 2015-04 ,pp. : 366-375

John Wiley & Sons Inc

Access to resources Recommend Favorite

Simeprevir (TMC435) once daily with peginterferon‐α‐2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO‐4 study

By  

HEPATOLOGY RESEARCH, Vol. 45, Iss. 5, 2015-05 ,pp. : 501-513

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prevention of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Infection

By  

Oncology, Vol. 81, Iss. 1, 2011-12 ,pp. : 41-49

Karger

Access to resources Recommend Favorite